Evicenter
MarkdownMedical informationP&T meetings
Palazestrant (OP-1250)

Previously treated ER-positive HER2-negative advanced or metastatic breast cancer

Manufacturer
Olema Oncology
Last updated
256 sources

Section 4 of 6

Clinical evidence

221 evidence topics · 43 sources

Study summaries

OPERA-01

Objective
Location and study date
Registry dates
MilestoneRegistry record
Study start (actual)“2023-11-16”
Primary completion (estimated)“2026-10-31”
Study completion (estimated)“2028-02-29”
Study design
Eligibility criteria
Treatment
Study outcomes
Rationale for using progression-free survival by blinded independent central review as the primary endpoint
Statistical analysis description
Number of participants (Planned and analyzed)
Planned enrollment: registry record
Enrollment typeParticipants
Estimated“510”
Planned participants per arm
Part and armPlanned participants
Total“n = 510”
Part 1, each arm (palazestrant 90 mg, palazestrant 120 mg, standard-of-care endocrine therapy)“n = 40”
Part 2, each arm (palazestrant 90 mg, standard-of-care endocrine therapy)“n = 195 (total 235)”
Description of analysis sets
Results
Participant disposition

No evidence found.

Baseline characteristics

No evidence found.

Efficacy results

No evidence found.

Health-related quality of life and patient-reported outcomes

No evidence found.

Safety results

No evidence found.

Study limitations
Summary

No efficacy or safety results from OPERA-01 have been reported; enrollment is complete, and top-line results are anticipated in the first quarter of 2027. The trial is open label, with PFS assessed by blinded independent central review as the dual primary endpoint. The 90 mg Part 2 dose was chosen from Part 1 data with no formal statistical comparison. The control arm is endocrine monotherapy (fulvestrant or an aromatase inhibitor), and fulvestrant was recommended to participants who had not previously received it. Eligibility excludes participants with prior chemotherapy in the advanced or metastatic setting, prior elacestrant, or symptomatic visceral disease, permits at most one additional line of endocrine therapy after the endocrine therapy and CDK4/6 inhibitor combination, and requires the most recent endocrine therapy to have lasted at least 6 months. Participants receive a tablet formulation, whereas the earlier monotherapy data were obtained with capsules. The trial design publication was funded by Olema Oncology, which was involved in the study design.

OP-1250-001

Objective
Location and study date
Study design
Eligibility criteria
Treatment
Study outcomes
Rationale for using dose-limiting toxicity as the primary endpoint
Statistical analysis description
Number of participants (Planned and analyzed)
Description of analysis sets
Results
Participant disposition
Baseline characteristics
Baseline characteristics at 60 and 120 mg/day
Characteristic60 mg (n = 30)120 mg (n = 86)Total (N = 116)
Age, years; median (range)“59.5 (30–81)”View highlighted excerpt for this quote“61.0 (32–85)”View highlighted excerpt for this quote“61.0 (30–85)”View highlighted excerpt for this quote
Female, n (%)“30 (100)”View highlighted excerpt for this quote“86 (100)”View highlighted excerpt for this quote“116 (100)”View highlighted excerpt for this quote
White, n (%)“23 (76.7)”View highlighted excerpt for this quote“70 (81.4)”View highlighted excerpt for this quote“93 (80.2)”View highlighted excerpt for this quote
Black or African American, n (%)“1 (3.3)”View highlighted excerpt for this quote“7 (8.1)”View highlighted excerpt for this quote“8 (6.9)”View highlighted excerpt for this quote
Asian, n (%)“1 (3.3)”View highlighted excerpt for this quote“3 (3.5)”View highlighted excerpt for this quote“4 (3.4)”View highlighted excerpt for this quote
Race not reported or other, n (%)“5 (16.7)”View highlighted excerpt for this quote“6 (7.0)”View highlighted excerpt for this quote“11 (9.5)”View highlighted excerpt for this quote
Childbearing potential, n (%)“0”View highlighted excerpt for this quote“7 (8.1)”View highlighted excerpt for this quote“7 (6.0)”View highlighted excerpt for this quote
ECOG performance status 0, n (%)“19 (63.3)”View highlighted excerpt for this quote“46 (53.5)”View highlighted excerpt for this quote“65 (56.0)”View highlighted excerpt for this quote
ECOG performance status 1, n (%)“11 (36.7)”View highlighted excerpt for this quote“40 (46.5)”View highlighted excerpt for this quote“51 (44.0)”View highlighted excerpt for this quote
Measurable disease, n (%)“29 (96.7)”View highlighted excerpt for this quote“69 (80.2)”View highlighted excerpt for this quote“98 (84.5)”View highlighted excerpt for this quote
Visceral disease, n (%)“24 (80.0)”View highlighted excerpt for this quote“61 (70.9)”View highlighted excerpt for this quote“85 (73.3)”View highlighted excerpt for this quote
1 prior line of therapy in advanced setting, n (%)“9 (30)”View highlighted excerpt for this quote“21 (24.4)”View highlighted excerpt for this quote“30 (25.9)”View highlighted excerpt for this quote
2 prior lines of therapy in advanced setting, n (%)“6 (20.0)”View highlighted excerpt for this quote“29 (33.7)”View highlighted excerpt for this quote“35 (30.2)”View highlighted excerpt for this quote
3 prior lines of therapy in advanced setting, n (%)“6 (20.0)”View highlighted excerpt for this quote“19 (22.1)”View highlighted excerpt for this quote“25 (21.6)”View highlighted excerpt for this quote
4 prior lines of therapy in advanced setting, n (%)“6 (20.0)”View highlighted excerpt for this quote“10 (11.6)”View highlighted excerpt for this quote“16 (13.8)”View highlighted excerpt for this quote
5 or more prior lines of therapy in advanced setting, n (%)“3 (10.0)”View highlighted excerpt for this quote“7 (8.1)”View highlighted excerpt for this quote“10 (8.6)”View highlighted excerpt for this quote
1 prior line of endocrine therapy in advanced setting, n (%)“12 (40.0)”View highlighted excerpt for this quote“30 (34.9)”View highlighted excerpt for this quote“42 (36.2)”View highlighted excerpt for this quote
2 prior lines of endocrine therapy in advanced setting, n (%)“7 (23.3)”View highlighted excerpt for this quote“32 (37.2)”View highlighted excerpt for this quote“39 (33.6)”View highlighted excerpt for this quote
3 prior lines of endocrine therapy in advanced setting, n (%)“7 (23.3)”View highlighted excerpt for this quote“15 (17.4)”View highlighted excerpt for this quote“22 (19.0)”View highlighted excerpt for this quote
4 prior lines of endocrine therapy in advanced setting, n (%)“3 (10.0)”View highlighted excerpt for this quote“8 (9.3)”View highlighted excerpt for this quote“11 (9.5)”View highlighted excerpt for this quote
5 prior lines of endocrine therapy in advanced setting, n (%)“1 (3.3)”View highlighted excerpt for this quote“1 (1.2)”View highlighted excerpt for this quote“2 (1.7)”View highlighted excerpt for this quote
Prior CDK4/6 inhibitor, n (%)“28 (93.3)”View highlighted excerpt for this quote“83 (96.5)”View highlighted excerpt for this quote“111 (95.7)”View highlighted excerpt for this quote
Prior aromatase inhibitor, n (%)“23 (76.7)”View highlighted excerpt for this quote“73 (84.9)”View highlighted excerpt for this quote“96 (82.8)”View highlighted excerpt for this quote
Prior fulvestrant, n (%)“19 (63.3)”View highlighted excerpt for this quote“57 (66.3)”View highlighted excerpt for this quote“76 (65.5)”View highlighted excerpt for this quote
Prior chemotherapy, n (%)“12 (40.0)”View highlighted excerpt for this quote“27 (31.4)”View highlighted excerpt for this quote“39 (33.6)”View highlighted excerpt for this quote
ESR1 mutations (ctDNA) at baseline, n/N (%)“15/21 (71.4)”View highlighted excerpt for this quote“36/75 (48.0)”View highlighted excerpt for this quote“51/96 (53.1)”View highlighted excerpt for this quote
Efficacy results
Response and clinical benefit by dose level
Endpoint60 mg/day120 mg/day
Response-evaluable participants with measurable disease“(n = 26)”View highlighted excerpt for this quote“66 response-evaluable patients treated with 120 mg/day palazestrant”View highlighted excerpt for this quote
Confirmed partial responses“2 confirmed PRs (cPRs; 7.7%)”View highlighted excerpt for this quote“3 confirmed PRs (4.5%)”View highlighted excerpt for this quote
Unconfirmed partial responses“1 unconfirmed PR (3.8%)”View highlighted excerpt for this quote“2 unconfirmed PRs (3.0%)”View highlighted excerpt for this quote
All partial responses“a total of 3 PRs (11.5%)”View highlighted excerpt for this quote“a total of 5 PRs (7.6%)”View highlighted excerpt for this quote
Clinical benefit rate, all evaluable participants“19.2% (95% CI, 6.6–39.4)”View highlighted excerpt for this quote“45.7% (95% CI, 33.7–58.1)”View highlighted excerpt for this quote
Participants evaluable for clinical benefit rate“(n = 26)”View highlighted excerpt for this quote“(n = 70)”View highlighted excerpt for this quote
Clinical benefit rate, ESR1 mutation“23.1% (95% CI, 5.0–53.8)”View highlighted excerpt for this quote“58.6% (95% CI, 38.9–76.5)”View highlighted excerpt for this quote
Participants with ESR1 mutation evaluable for clinical benefit rate“among the 13 patients with cancers with ESR1 mutations”View highlighted excerpt for this quote“(n = 29)”View highlighted excerpt for this quote
Second- or third-line subset at 120 mg (conference presentation)
PopulationMedian PFS, months [95% CI]6-month PFSCBR
All participants (n=86)“4.6 [3.5, 6.5]”“38%”“40%”
Second or third line with or without chemotherapy (n=49)“7.2 [3.7, 7.8]”“54%”“48%”
ESR1 mutation (n=36)“5.6 [3.7, 7.8]”“46%”“52%”
ESR1 mutation, second or third line with or without chemotherapy (n=23)“7.3 [5.0, NA]”“62%”“59%”
Health-related quality of life and patient-reported outcomes

No evidence found.

Safety results
Adverse events occurring in at least 15% of participants, n (%)
Event60 mg any grade (n = 30)60 mg grade 360 mg grade 4120 mg any grade (n = 86)120 mg grade 3120 mg grade 4
TEAE: nausea“14 (46.7)”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“54 (62.8)”View highlighted excerpt for this quote“3 (3.5)”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote
TEAE: vomiting“5 (16.7)”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“25 (29.1)”View highlighted excerpt for this quote“4 (4.7)”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote
TEAE: fatigue“13 (43.3)”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“22 (25.6)”View highlighted excerpt for this quote“3 (3.5)”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote
TEAE: neutropenia“2 (6.7)”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“21 (24.4)”View highlighted excerpt for this quote“3 (3.5)”View highlighted excerpt for this quote“6 (7.0)”View highlighted excerpt for this quote
TEAE: headache“7 (23.3)”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“17 (19.8)”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote
TEAE: constipation“6 (20.0)”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“15 (17.4)”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote
TEAE: diarrhea“6 (20.0)”View highlighted excerpt for this quote“1 (3.3)”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“12 (14.0)”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote
TRAE: nausea“10 (33.3)”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“47 (54.7)”View highlighted excerpt for this quote“3 (3.5)”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote
TRAE: vomiting“3 (10.0)”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“21 (24.4)”View highlighted excerpt for this quote“2 (2.3)”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote
TRAE: fatigue“9 (30.0)”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“17 (19.8)”View highlighted excerpt for this quote“2 (2.3)”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote
TRAE: neutropenia“0”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“18 (20.9)”View highlighted excerpt for this quote“3 (3.5)”View highlighted excerpt for this quote“5 (5.8)”View highlighted excerpt for this quote
TRAE: headache“3 (10.0)”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“13 (15.1)”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote
Aspartate aminotransferase increase at 120 mg (conference presentation, N=83)
EventGrade 1Grade 2Grade 3Grade 4All, n (%)
AST increased“10”“2”“1”“0”“13 (16)”
Study limitations
Summary

OP-1250-001 was an open-label phase 1/2 study without a comparator arm, which the authors state limits interpretation of the safety profile and antitumor activity. Efficacy estimates come from dose cohorts of 30 participants at 60 mg/day and 86 at 120 mg/day, and only 6 participants were enrolled at 90 mg/day, during dose escalation. Response and CBR analyses used restricted populations: response required measurable disease and a postbaseline assessment (66 response-evaluable participants at 120 mg/day), and the CBR analysis excluded participants who discontinued without radiographic progression within 24 weeks. Two reports of the 120 mg cohort give different values: the peer-reviewed publication reports a CBR of 45.7% in 70 evaluable participants and a median PFS of 4.8 months, and the 2023 conference presentation reports a CBR of 40% (32/81) and a median PFS of 4.6 months. The study excluded primary endocrine resistance; fasted dosing, the exclusion of proton pump inhibitors and most common antiemetics, and a relatively large capsule may have increased gastrointestinal events. The central nervous system metastases cohort is not included in the publication, and the association between ESR1 mutation reduction and CBR is based on 11 and 32 participants (CBR 73% [8/11] versus 25% [8/32]). All 116 participants treated at 60 or 120 mg/day were women, 33.6% had received prior chemotherapy, and 8.6% had received 5 or more prior lines of therapy in the advanced setting.

OP-1250-003

Objective
Location and study date
Registry dates and planned enrollment
ItemValue
Study start (actual)“2022-08-31”
Primary completion (estimated)“2027-12-31”
Study completion (estimated)“2028-01-31”
Enrollment (estimated)“190”
Study design
Eligibility criteria
Treatment
Study outcomes
Rationale for using dose-limiting toxicities as the primary endpoint
Statistical analysis description
Number of participants (Planned and analyzed)
Ribociclib group: participants by cohort, July 2025 data cutoff
CohortParticipants
Dose escalation, palazestrant 30 mg“30 mg (n=3)”
Dose escalation, palazestrant 60 mg“60 mg (n=3)”
Dose escalation, palazestrant 120 mg“120 mg (n=3)”
Dose expansion, palazestrant 90 mg“90 mg (n=16)”
Dose expansion, palazestrant 120 mg“120 mg (n=53)”
Description of analysis sets
Results
Participant disposition
Baseline characteristics
Ribociclib group: baseline demographics and disease characteristics, July 2025 data cutoff
CharacteristicPalazestrant 90 mg (n=16)Palazestrant 120 mg (n=56)Total (N=72)
Median age, years (range)“60 (25-76)”“61 (28-85)”“61 (25-85)”
Female sex, n (%)“16 (100%)”“56 (100%)”“72 (100%)”
Premenopausal, n (%)“4 (25%)”“8 (14%)”“12 (17%)”
ECOG performance status 0, n (%)“10 (63%)”“34 (61%)”“44 (61%)”
ECOG performance status 1, n (%)“6 (38%)”“22 (39%)”“28 (39%)”
Measurable disease at baseline, n (%)“12 (75%)”“37 (66%)”“49 (68%)”
Visceral disease, n (%)“6 (38%)”“33 (59%)”“39 (54%)”
No prior line of therapy in the advanced setting, n (%)“10 (63%)”“14 (25%)”“24 (33%)”
One prior line of therapy in the advanced setting, n (%)“5 (31%)”“26 (46%)”“31 (43%)”
Two prior lines of therapy in the advanced setting, n (%)“1 (6.3%)”“12 (21%)”“13 (18%)”
Three prior lines of therapy in the advanced setting, n (%)“0”“4 (7%)”“4 (6%)”
Prior CDK4/6 inhibitor in the advanced setting, n (%)“5 (31%)”“40 (71%)”“45 (63%)”
Prior aromatase inhibitor in the advanced setting, n (%)“5 (31%)”“27 (48%)”“32 (44%)”
Prior fulvestrant in the advanced setting, n (%)“1 (6%)”“22 (39%)”“23 (32%)”
Prior chemotherapy in the advanced setting, n (%)“1 (6.3%)”“10 (18%)”“11 (15%)”
ESR1 mutation at baseline“1/15 (7%)”“14/54 (26%)”“15/69 (22%)”
Efficacy results
Ribociclib group: objective response rate, July 2025 data cutoff
PopulationObjective response rate (n/n)
90 mg cohort (n=12)“42% (5/12)”
120 mg cohort (n=32)“31% (10/32)”
Prior CDK4/6i, 120 mg cohort (n=23)“26% (6/23)”
All (n=44)“34% (15/44)”
Ribociclib group: steady-state ribociclib 600 mg exposure, October 2023 data cutoff
ParameterRibociclib single agentRibociclib in combination with palazestrant
AUC0-24 ([h*ng/mL]/mg), GeoMean (GeoCV); N“23,800 (66%); 54”“25,400 (78%); 8”
Cmax (ng/mL/mg), GeoMean (GeoCV); N“1,820 (62%); 57”“1,860 (66%); 8”
Tmax (h), Median (min–max); N“2.4 (0.68–7.8); 57”“4.0 (1.0–6.0); 8”
Health-related quality of life and patient-reported outcomes

No evidence found.

Safety results
Ribociclib group: related treatment-emergent adverse events in at least 25% of participants, n (%)
Event120 mg (n=56), all grades120 mg, grade 3120 mg, grade 490 mg (n=16), all grades90 mg, grade 390 mg, grade 4
Neutropenia (combined term)“47 (84%)”“28 (50%)”“5 (9%)”“13 (81%)”“9 (56%)”“2 (16%)”
Nausea“41 (73%)”“2 (4%)”“0”“11 (69%)”“1 (6%)”“0”
Fatigue“30 (54%)”“3 (5%)”“0”“9 (50%)”“0”“0”
White blood cell decrease“24 (43%)”“9 (16%)”“1 (2%)”“6 (38%)”“4 (25%)”“0”
Diarrhea“24 (43%)”“2 (4%)”“0”“4 (25%)”“0”“0”
Anemia“22 (39%)”“2 (4%)”“0”“5 (31%)”“0”“0”
Vomiting“21 (38%)”“1 (2%)”“0”“4 (25%)”“0”“0”
Electrocardiogram QT prolonged“16 (29%)”“4 (5%)”“0”“4 (25%)”“1 (6%)”“0”
Lymphocyte decrease“16 (29%)”“3 (5%)”“1 (2%)”“3 (19%)”“0”“0”
AST increased“15 (27%)”“2 (4%)”“0”“3 (19%)”“0”“0”
Constipation“15 (27%)”“0”“0”“3 (19%)”“0”“0”
Study limitations
Summary

OP-1250-003 is an open-label phase 1b, 2-part study in 4 treatment groups, and the 2025 presentation cautions that its comparison aggregates results across independent studies and carries the risks inherent in cross-trial comparisons. The ribociclib group population differs from this indication: 24 of 72 participants (33%) had no prior line of therapy in the advanced setting, and 45 (63%) had received a prior CDK4/6 inhibitor. Cohorts include 16 participants at palazestrant 90 mg and 56 at 120 mg, and response rates are based on 12 and 32 response-evaluable participants, respectively. The presentation describes efficacy as “maturing”: 30 of 72 participants (42%) remained on treatment at the July 8, 2025 cutoff, and median PFS in the 90 mg cohort was not reached at a median follow-up of 10.8 months. Responses were assessed by the investigator, and the analysis presented 72 of 78 enrolled participants. Interim results were reported at successive cutoffs (March 13, 2024; September 25, 2024; and July 8, 2025) with different analysis populations.

OP-1250-002

Objective
Location and study date
Registry dates and enrollment
ItemValue
Study start (actual)“2021-12-10”
Primary completion (estimated)“2026-03”
Enrollment (actual)“60”
Study design
Eligibility criteria
Treatment
Study outcomes
Rationale for using dose-limiting toxicities as the primary endpoint
Statistical analysis description
Number of participants (Planned and analyzed)
Participants by palazestrant dose, September 2023 data cutoff
Description of analysis sets
Results
Participant disposition
Treatment status and reasons for discontinuation, September 2023 data cutoff
StatusTotal (N=46), n (%)
Treatment ongoing“22 (48)”
Treatment discontinued“24 (52)”
Discontinued for disease progression“18 (39)”
Discontinued for physician decision“3 (7)”
Discontinued for patient decision“2 (4)”
Discontinued for adverse event“1 (2)”
Baseline characteristics
Baseline demographics and disease characteristics, September 2023 data cutoff
CharacteristicTotal (N=46), n (%)
Median age, years (range)“63.5 (30–77)”
Female sex“45 (98)”
Premenopausal“4 (9)”
ECOG performance status 0“31 (67)”
ECOG performance status 1“15 (33)”
Measurable disease“36 (78)”
Visceral disease“20 (44)”
One prior line of therapy for advanced disease“34 (74)”
One prior line of endocrine therapy for advanced disease“40 (87)”
Prior CDK4/6 inhibitor for advanced disease“33 (72)”
Prior aromatase inhibitor for advanced disease“35 (76)”
Prior fulvestrant for advanced disease“5 (11)”
Prior chemotherapy for advanced disease“10 (22)”
ESR1 mutation at baseline (ctDNA)“16/37 (43)”
Efficacy results
Health-related quality of life and patient-reported outcomes

No evidence found.

Safety results
Treatment-emergent adverse events in at least 20% of participants, total population (N=46), n (%)
EventAll gradesGrade 3Grade 4
Neutropenia (combined term)“40 (87)”“28 (61)”“5 (11)”
Nausea“26 (57)”“0”“0”
Vomiting“17 (37)”“0”“0”
Anemia“12 (26)”“1 (2)”“0”
Diarrhea“11 (24)”“0”“0”
Constipation“10 (22)”“1 (2)”“0”
Fatigue“10 (22)”“1 (2)”“0”
Thrombocytopenia“10 (22)”“0”“0”
Study limitations
Summary

OP-1250-002 is an open-label phase 1b dose-escalation and dose-expansion study. Eligibility allowed zero or one prior endocrine therapy with or without a CDK4/6 inhibitor for advanced disease, which admits participants outside previously treated disease; 33 of 46 participants (72%) had received a prior CDK4/6 inhibitor. The CBR is based on 26 evaluable participants overall and 10 with ESR1 mutations, and circulating tumor DNA for ESR1 testing was available for 37 participants. The reported results have a data cutoff of September 15, 2023, at which 22 participants (48%) remained on treatment and the data were described as maturing. The registry lists an actual enrollment of 60 participants, whereas the reported analysis includes 46.

OPERA-02

Objective
Location and study date
Registry dates and planned enrollment
ItemValue
Study start (actual)“2025-11-03”
Primary completion (estimated)“2028-12”
Study completion (estimated)“2032-01”
Study design
Eligibility criteria
Treatment
Study outcomes
Rationale for using investigator-assessed progression-free survival as the primary endpoint
Primary, key secondary, and other secondary endpoints
Endpoint roleEndpoint
Primary endpoint“PFS, as assessed by local investigator”
Key secondary endpoint“OS”
Other secondary endpoint“PFS (per BIRC)”
Other secondary endpoint“ORR, CBR, and DOR (per local investigator and BIRC)”
Other secondary endpoint“PFS2”
Other secondary endpoint“Safety and tolerability”
Other secondary endpoint“PK”
Other secondary endpoint“Patient-reported outcomes”
Statistical analysis description
Number of participants (Planned and analyzed)
Description of analysis sets

No evidence found.

Results
Participant disposition

No evidence found.

Baseline characteristics

No evidence found.

Efficacy results

No evidence found.

Health-related quality of life and patient-reported outcomes

No evidence found.

Safety results

No evidence found.

Study limitations
Summary

No results from OPERA-02 have been reported; primary completion is estimated for December 2028, and top-line data are anticipated in 2028. The trial enrolls participants with no prior systemic therapy for advanced breast cancer and tests palazestrant in combination with ribociclib, so its population and regimen are outside this indication of previously treated disease and palazestrant monotherapy. The primary endpoint is investigator-assessed PFS, with PFS by blinded independent central review as a secondary endpoint. Participants previously treated with fulvestrant, elacestrant, or an investigational endocrine therapy in any setting are excluded.